Daily Newsletter

11 October 2023

Daily Newsletter

11 October 2023

Xenix Medical secures FDA clearance for spinal fusion nanotech implants

The micro and nano-roughened surface was designed to improve fixation of the interbody fusion implant to the adjacent bone.

Robert Barrie October 11 2023

The US Food and Drug Administration (FDA) has cleared Xenix Medical’s interbody fusion implants that feature the company’s proprietary nanotechnology.

Florida, US-based Xenix Medical developed nanotechnology for its neoWave line of interbody fusion implants – devices used for the treatment of degenerative lumbar disease.

In a statement announcing the 510(k) clearance from the FDA, Xenix Medical said it designed the nanotechnology, called NANOACTIV, to improve fixation to the adjacent bone. The company says its micro and nano-roughened surface has demonstrated the ability to elicit an endogenous cellular and biochemical response.

The neoWave implants themselves consist of a 3D-printed lattice, with Xenix Medical saying the matrix increases endplate surface area and resists subsidence compared to traditional implants. The company says more than 7,000 of its devices have been implanted in the US.

A market model by GlobalData estimates the spinal fusion device global market will be worth $11.1bn by 2033, with the interbody devices market segment contributing $5.4bn.

Justin Brown, associate professor of biomedical engineering at Pennsylvania State University, said in the company statement: “Our evaluation of the NANOACTIV surface technology revealed that the micro- and nanoscale features generated a bioinstructive interface that promoted robust osteogenic differentiation of mesenchymal stem cells.”

Nanotechnology is a promising area in medicine – with applications in areas such as cancer research, regenerative medicine and orthopaedics. The National Institutes of Health says it invests more than $200m a year in nanotechnology research.

In September 2023, the White House Office of Science and Technology Policy and the National Nanotechnology Coordination Office held a summit to discuss streamlining and advancing nanotechnology research.

Healthcare companies are hesitant to invest in the metaverse

Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close